Pereira, Pedro A. B. http://orcid.org/0000-0002-2967-2252
Trivedi, Drupad K. http://orcid.org/0000-0001-7969-0195
Silverman, Justin
Duru, Ilhan Cem
Paulin, Lars http://orcid.org/0000-0003-0923-1254
Auvinen, Petri http://orcid.org/0000-0002-3947-4778
Scheperjans, Filip http://orcid.org/0000-0001-9502-7131
Funding for this research was provided by:
Academy of Finland (295724, 310835)
Suomen Lääketieteen Säätiö
Hospital District of Helsinki and Uusimaa (HUS) https://www.hus.fi/en/about-us
Michael J. Fox Foundation for Parkinson’s Research
Michael J. Fox Foundation for Parkinson’s Research
Michael J. Fox Foundation for Parkinson’s Research
Michael J. Fox Foundation for Parkinson’s Research
Michael J. Fox Foundation for Parkinson’s Research
Article History
Received: 13 July 2021
Accepted: 4 March 2022
First Online: 11 April 2022
Competing interests
: P.A.B.P., L.P., P.A. and F.S. have patents issued (FI127671B & US10139408B2) and pending (US16/186,663 & EP3149205) that are assigned to NeuroBiome Ltd. F.S. is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics. Authors J.S., I.C.D. and J.S. declare no competing interests.